European Urology Oncology

Slides:

Advertisements

Similar presentations

Maria Carmen Mir, Cesar Ercole, Andrew Stephenson

Advertisements

Oncol Res Treat 2016;39: DOI: /

A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) Giorgio Arcangeli,

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

European Urology Focus

Volume 66, Issue 6, Pages (December 2014)

European Urology Focus

Volume 199, Issue 4, Pages e235-e236 (April 2018)

Volume 68, Issue 3, Pages (September 2015)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 3, Pages (March 2007)

European Urology Oncology

Volume 72, Issue 5, Pages (November 2017)

Volume 52, Issue 4, Pages (October 2007)

Volume 61, Issue 4, Pages (April 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 66, Issue 3, Pages (September 2014)

Volume 63, Issue 1, Pages (January 2013)

European Urology Oncology

European Urology Oncology

Volume 61, Issue 5, Pages (May 2012)

Volume 68, Issue 1, Pages 5-7 (July 2015)

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 64, Issue 5, Pages (November 2013)

Volume 61, Issue 6, Pages (June 2012)

Volume 64, Issue 3, Pages (September 2013)

European Urology Oncology

Volume 148, Issue 1, Pages (January 2018)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 71, Issue 6, Pages (June 2017)

Stephen B. Williams, Ashish M

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 64, Issue 4, Pages (October 2013)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 2, Pages (August 2014)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 53, Issue 1, Pages (January 2008)

Volume 62, Issue 3, Pages (September 2012)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

European Urology Oncology

European Urology Oncology

Volume 71, Issue 5, Pages (May 2017)

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

European Urology Oncology

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

European Urology Oncology

European Urology Oncology

Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder Devin N. Patel, Michael Luu, Zachary.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

European Urology Oncology

The Cost to Medicare of Bladder Cancer Care

Volume 75, Issue 2, Pages (February 2019)

Axel Heidenreich European Urology Supplements

Volume 52, Issue 4, Pages (October 2007)

European Urology Oncology

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

European Urology Oncology

European Urology Oncology

Maximilian Burger, Ashish M. Kamat, David McConkey

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Presentation transcript:

European Urology Oncology Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes Luca Boeri, Matteo Soligo, Igor Frank, Stephen A. Boorjian, R. Houston Thompson, Matthew Tollefson, Fernando J. Quevedo, John C. Cheville, R. Jeffrey Karnes European Urology Oncology DOI: 10.1016/j.euo.2018.09.004 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier plots depicting the overall mortality (OM)-free rate among patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy between 1999 and 2015 at a single centre, stratified according to time to cystectomy (TTC; >10wk vs ≤10wk). European Urology Oncology DOI: (10.1016/j.euo.2018.09.004) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier plots depicting the cancer-specific mortality (CSM)-free rate among patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy between 1999 and 2015 at a single centre, stratified according to time to cystectomy (TTC; >10wk vs ≤10wk). European Urology Oncology DOI: (10.1016/j.euo.2018.09.004) Copyright © 2018 European Association of Urology Terms and Conditions